Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jaron Winston

Geriatric Psychiatry Austin, TX Medical Doctor

NPI 1568463420 CMS profile 162087

3215 Steck Ave, Suite 200, Austin, TX 78757

Open in the dashboard

General payments

$5,996

255 records reported · program years 2019–2025

Research payments

$16,394

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$6,805,354 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jaron Winston of Austin, TX is reported in the CMS Open Payments database as having received $5,996 across 255 general payments and $16,394 in research payments paid to them. Separately, studies naming them as principal investigator received $6,805,354 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Geriatric Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $664 25
2024 General $2,169 50
2023 General $678 33
2023 Research $7,955 3
2022 General $515 27
2022 Research $7,429 2
2021 General $487 25
2021 Research $1,009 1
2020 General $285 15
2019 General $1,197 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jaron Winston
  • Geriatric Psychiatry median
  • Middle half of Geriatric Psychiatry
  • National median

In program year 2025, general payments to Jaron Winston were reported at $664. Among 188 Geriatric Psychiatry profiles paid that year, the median was $125 and the middle half received between $52 and $515.

Show as a table
Year Jaron Winston Geriatric Psychiatry median Middle half National median
2019 $1,197 $151 $47–$484 $163
2020 $285 $112 $30–$410 $114
2021 $487 $122 $35–$550 $132
2022 $515 $133 $54–$557 $149
2023 $678 $138 $61–$485 $160
2024 $2,169 $127 $51–$572 $164
2025 $664 $125 $52–$515 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $1,165 3 payments
  2. Lundbeck LLC $629 29 payments
  3. Teva Pharmaceuticals USA, Inc. $604 32 payments
  4. Neurocrine Biosciences, Inc. $547 32 payments
  5. Janssen Pharmaceuticals, Inc $542 23 payments
  6. ACADIA Pharmaceuticals Inc $411 22 payments
  7. Otsuka America Pharmaceutical, Inc. $300 14 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $226 13 payments
  9. Allergan Inc. $221 22 payments
  10. AbbVie, Inc. $213 10 payments
  11. Other $1,137 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,138 253 payments
  2. Travel and Lodging $857 2 payments
Products named General payments · program years 2019–2025
  1. REXULTI Psychiatry $589 27 payments
  2. SPRAVATO $531 22 payments
  3. AUSTEDO $424 23 payments
  4. REXULTI Psychiatry $284 13 payments
  5. INGREZZA Neuropsychiatry $265 12 payments
  6. VRAYLAR $234 22 payments
  7. INGREZZA Neurology $223 17 payments
  8. NUPLAZID Parkinsons Disease Psychosis $208 12 payments
  9. NUPLAZID Parkinsons Disease Psychosis $203 10 payments
  10. Austedo XR $181 9 payments
  11. Other $1,709 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $16,394 6 payments

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

3,115

Median for Psychiatry: 574

Drug cost

$377,325

Median for Psychiatry: $27,624

Branded share of claims

30.6%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 12 $168,123
Vyvanse Lisdexamfetamine Dimesylate Brand 64 $34,511
Lisdexamfetamine Dimesylate Generic 130 $25,769
Trintellix Vortioxetine Hydrobromide Brand 28 $23,375
Belsomra Suvorexant Brand 30 $15,621
Lexapro Escitalopram Oxalate Brand 30 $14,467
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 314 $11,711
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 80 $9,246
Rivastigmine Generic 32 $6,907
Methylphenidate Hcl Generic 142 $4,861

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$144,952

Medicare's payments for the services billed

Medicare patients

217

Average age 78

Services billed

1,552

145 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Arthritis 58%
Ischemic heart disease 32%
Diabetes 27%
Osteoporosis 22%
Chronic kidney disease 21%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $277
  • Otsuka America Pharmaceutical, Inc. $61
$337 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $133
$133 12 —
VRAYLAR
  • AbbVie, Inc. $74
$74 — —
AMYVID
  • Lilly USA, LLC $74
$74 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

261 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Psychiatry in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record